Clinical trial · no report yet · Phase 2
NCT03794544
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
- NCT03794544 ↗
- Completed
- MedImmune LLC
- 19 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 9 | |
| YouTube | 7 | |
| Podcasts | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Open-label, Multicenter, Randomized, Multidrug Platform Study of Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Subjects With Resectable, Early-stage (I [> 2 cm] to IIIA) Non-small Cell Lung Cancer (NeoCOAST)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Resectable; Early-stage; NSCLC
- Interventions
- Durvalumab; Oleclumab; Monalizumab; Danvatirsen
- Arms
- Durvalumab 1500 mg · Experimental
- Durvalumab 1500 mg + Oleclumab 3000 mg · Experimental
- Durvalumab 1500 mg + Monalizumab 750 mg · Experimental
- Durvalumab 1500 mg + Danvatirsen 200 mg · Experimental
- Enrollment
- 84
- Primary outcomes
- Major Pathological Response Rate
- Sponsor
- MedImmune LLC
- Start
- Mar 8, 2019
- Primary completion
- Jan 13, 2021
- Results posted
- Yes
- Registry record
- NCT03794544 · updated Feb 24, 2022
Publications
linked from the registry- Cascone T, Kar G, Spicer JD, Garcia-Campelo R, Weder W, Daniel DB, Spigel DR, Hussein M, Mazieres J, Oliveira J, Yau EH, Spira AI, Anagnostou V, Mager R, Hamid O, Cheng LY, Zheng Y, Blando J, Tan TH, Surace M, Rodriguez-Canales J, Gopalakrishnan V, Sellman BR, Grenga I, Soo-Hoo Y, Kumar R, McGrath L, Forde PM. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial. Cancer Discov. 2023 Nov 1;13(11):2394-2411. doi: 10.1158/2159-8290.CD-23-0436. PubMed 37707791